Cytori Therapeutics (CYTX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 3Q15
November 9, 2015 8:40 AM ESTRoth Capital maintained a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target of $2.50 (from $4.00), following the company's 3Q15 earnings report. CYTX reported EPS of $0.01 compared with the consensus estimate of ($0.06).
Analyst Joseph Pantginis commented, "With four potential approval... More
